Acceptance-based Healthy Lifestyles Program for Patients With Pneumoconiosis
Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 20, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a program designed to help patients with pneumoconiosis, a lung condition that often causes symptoms like coughing and shortness of breath. The goal is to see if an educational program that encourages acceptance of their condition can help patients manage their symptoms better and improve their overall well-being. The study will involve 80 participants who will be divided into two groups: one will start the program right away, while the other will wait for six weeks before participating. The program includes four sessions that focus on both acceptance techniques and caring for their lung health. Researchers will check in with participants at the start, after six weeks, and again after 14 weeks to see how they are doing.
To be eligible for the trial, participants must be ethnic Chinese adults aged 18 or older who are currently receiving compensation for their pneumoconiosis. However, individuals with certain mental or sensory impairments, or those unable to provide written consent, will not be able to join. This study aims to explore new ways to support people with pneumoconiosis and could lead to better management strategies for this condition and other chronic lung diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Ethnic Chinese who is able read and speak Chinese.
- • 2. Adults aged 18 or over.
- • 3. Taking compensation for pneumoconiosis.
- Exclusion Criteria:
- • 1. Those who have mental, visual, hearing, or cognitive impairments with regular medical follow-ups and treatment.
- • 2. Those who are unable to give written consent.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported